Program

September 28, 2016

7:30 AM Registration – Lobby
7:45 AM Breakfast – The Pechet Room
8:45 AM Welcome Remarks – Amphitheatre
9:00 AM – 10:20 AM

WHY ASIA? – Understanding the opportunities for partnering and financing in the Asian markets including the epidemiology of Asia 

  • William Cacheris, President, Tessellon Inc.
  • Chris Francis, PhD, Senior Vice President, Corporate Development & Portfolio Management, WAVE Life Sciences
  • Matt Heimerdinger, Research Director, Anterio Inc.
  • James B. Weissman, CBO, Dicerna Pharmaceuticals
  • Nat Whitney, President, Whitney Research
10:20 AM – 10:35 AM Break
10:35 AM – 11:25 AM

BUILDING YOUR ASIAN IQ – The key issues to understand and the steps to take in Asia  

  • Larry Cai, Head of Business Development, New England, Qilu Pharmaceuticals
  • Sara Jane Demy, Founder & CEO, Demy-Colton
  • James Foley, PhD, Managing Director, Aqua Partners LLC
  • Charles Hsu, PhD, Managing Partner, Crosswave Management
11:30 AM – 12:25 PM

FOCUS ON SIMILARITIES AND DIFFERENCES – Parsing the myths, true and untrue, about China, Korea and Japan

  • James Foley, PhD, Managing Director, Aqua Partners LLC
  • Charles Hsu, PhD, Managing Partner, Crosswave Management
  • Alan Seem, Partner, Shearman & Sterling LLP
  • Jeff Tomlinson, CBO, ASLAN Pharmaceuticals
12:30 PM – 1:40 PM Lunch with the Experts
1:45 PM – 2:40 PM

MONEY IN ASIA – Investing in biotech companies in Asia and North America

  • David H. Deming, Managing Partner, TAG Healthcare Advisors
  • Wenseng Wendy Pan, PhD, Partner, Sidley Austin LLP
  • Mark Tang, Managing Director, Good Health Capital
  • Jimmy Zhang, PhD, Managing Director, Cross-Border Investment, CL Investment Group
2:40 PM – 2:55 PM Break
2:55 PM – 3:40 PM

CLINICAL TRIAL DESIGN IN ASIA – Collaborating with CROs and CMOs on where you run your study and where you manufacture

  • Pey Ni Chan, Managing Director, CMIC Asia-Pacific, Pte. Ltd.
  • RuiPing Dong, Managing Director, RuiPing Consulting
  • Keiko Oishi, Senior Managing Director, CMIC Co., Ltd
  • Gunther Winkler, Co-Founder and CEO, Biometheus LLC
3:45 PM – 4:55 PM

THE DEAL LANDSCAPE – An inside look at the cross-border deals including successful deals, unsuccessful deals and breakthrough deals

  • Sean Cao, PhD, Vice President, Global Business Development, Simcere Pharmaceutical Group
  • Kimberly Ha, Senior Director Strategic Communications, FTI Consulting
  • Mark Tang, Managing Director, Good Health Capital
  • Brianne Weingarten, Head of Alliance Management, Licensing & Business Development, Purdue Pharma L.P.
5:00 PM – 6:30 PM Networking Reception

September 29, 2016

7:45 AM Breakfast – The Pechet Room
8:45 AM – 9:55 AM

GLOBALIZATION OF THE ASIAN INDUSTRY – How North American biopharma companies can attract Asian innovation through outward and/or inward partnerships and investments 

  • Larry Cai, Head of Business Development, New England, Qilu Pharmaceuticals
  • Chris Francis, PhD, Senior Vice President, Corporate Development & Portfolio Management, WAVE Life Sciences
  • Julia P. Gregory, Former CEO, ContraFect Corporation
  • Derrick Li, Director, Investing and Licensing, North America, TPP Healthcare
  • Tim Opler, PhD, Partner, Torreya Partners
9:55 AM – 10:10 AM Break
10:10 AM – 11:05 AM

DUE DILIGENCE AND DEAL MAKING IN ASIA – What you need to know to avoid pitfalls and ensure an effective deal

  • Linda M. Pullan, PhD, Founder, Pullan Consulting
  • Jeff Tomlinson, CBO, ASLAN Pharmaceuticals
  • Xiaoming Zou, PhD, CEO, EOC Pharma
11:10 AM – 12:05 PM

THE COMPLEXITIES OF REGULATORY REGIMES – Understanding and navigating the various regulatory regimes in Asia

  • RuiPing Dong, Managing Director, RuiPing Consulting
  • Jurij Petrin, MD, President and Chief Executive Officer, Pharmaceutical Regulatory Services, Inc.
  • Bill Pignato, Founder and Principal, W.J. Pignato & Associates, LLC
12:10 PM– 1:20 PM Lunch with the Experts
1:25 PM – 2:20 PM

MANAGING INTELLECTUAL PROPERTY IN ASIA – The challenges and opportunities for biotech companies, including retaining US commercialization rights in license deals

  • Judy Jarecki-Black, PhD, Head, IP, Merial
  • Grace L. Pan, Partner, Holland & Knight LLP
  • Fang Xie, PhDCo-Leader, Biotechnology & Pharmaceutical Industry Group, Greenberg Traurig, LLP
2:25 PM – 3:30 PM

THE VIEW FROM BIG PHARMA – How does Big Pharma view the role of Trans-Pacific Partnerships?

  • Yuan-Hua Ding, Executive Director and Head of Pfizer External R&D Innovation (ERDI) – Asia/Pacific, Pfizer Worldwide Research & Development
  • Julia P. Gregory, Former CEO, ContraFect Corporation
  • James B. Weissman, CBO, Dicerna Pharmaceuticals
  • Wei Zhang, Investor, Lilly Asia Ventures
3:30 PM – 4:30 PM Closing Reception